Zhitong Finance App News, FuRui Medical Technology (01696) announced that it intends to exercise powers under the general authorization granted to the board of directors by shareholders of the Company at the annual general meeting of shareholders to be held on June 24, 2026. The board of directors has decided that, depending on market conditions, the Company intends to repurchase the Company's shares in the open market from time to time, up to 1% of the total number of shares issued by the Company as of the date of this announcement. The use of such repurchased shares (including cancellation of repurchased shares or holding treasury shares) will be determined by the Company in accordance with its capital management needs.
The board of directors believes that the share repurchase plan shows the company's confidence in its business prospects and long-term development, and will ultimately benefit the company and create value for shareholders. The Board believes that the implementation of the share repurchase plan will not adversely affect the Company's financial position or its day-to-day business processes. Therefore, the Board of Directors believes that implementing the share repurchase plan is in the overall interests of the Company and its shareholders.
The implementation of the share repurchase plan will be subject to share repurchase authorization, the applicable provisions of the Company's Articles of Association, the Hong Kong Stock Exchange Limited Securities Listing Rules, the “Code on Company Acquisitions, Mergers and Share Repurchases”, and other applicable laws and regulations. There is no guarantee on the timing, quantity, or price of any share repurchases.